Michael Morneau
Chief Administrative Officer bij VIKING THERAPEUTICS, INC.
Profiel
Michael Morneau's current job is Vice President-Finance & Administration at Viking Therapeutics, Inc. Mr. Morneau's former jobs include Director-Lilly Research Labs Finance at Eli Lilly & Co. from 2008 to 2009, Director-Finance & Accounting at SGX Pharmaceuticals, Inc. from 2006 to 2008, Controller at Gensym Corp.
from 2002 to 2004, Controller at Momenta Pharmaceuticals, Inc. from 2004 to 2006, and Chief Accounting Officer & Vice President at Trius Therapeutics, Inc. from 2009 to 2014.
Mr. Morneau's education includes a graduate degree and an MBA from Southern New Hampshire University, as well as an undergraduate degree from the University of New Hampshire.
Actieve functies van Michael Morneau
Bedrijven | Functie | Begin |
---|---|---|
VIKING THERAPEUTICS, INC. | Chief Administrative Officer | 01-05-2014 |
Eerdere bekende functies van Michael Morneau
Bedrijven | Functie | Einde |
---|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Director of Finance/CFO | 09-05-2011 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-01-2009 |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01-01-2008 |
MOMENTA PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01-01-2006 |
Gensym Corp.
Gensym Corp. Packaged SoftwareTechnology Services Gensym Corp. engages in the provision of software solutions and services. It offers real-time system development platform for building mission critical process control, production control, and simulation applications. The company was founded by Robert L. Moore & Lowell B. Hawkinson in 1986 and is headquartered in Burlington, MA. | Comptroller/Controller/Auditor | 01-01-2004 |
Opleiding van Michael Morneau
Southern New Hampshire University | Graduate Degree |
University of New Hampshire | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
VIKING THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Gensym Corp.
Gensym Corp. Packaged SoftwareTechnology Services Gensym Corp. engages in the provision of software solutions and services. It offers real-time system development platform for building mission critical process control, production control, and simulation applications. The company was founded by Robert L. Moore & Lowell B. Hawkinson in 1986 and is headquartered in Burlington, MA. | Technology Services |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |